Literature DB >> 12916922

Powder properties and their influence on dry powder inhaler delivery of an antitubercular drug.

Vasu V Sethuraman1, Anthony J Hickey.   

Abstract

The purpose of this study was to determine if aerosol delivery of drug loaded microparticles to lungs infected with Mycobacterium tuberculosis may be achieved by predicting dispersion of dry powders through knowledge of particle surface properties. Particle sizes of rifampicin-loaded poly(lactide-co-glycolide) microparticles (R-PLGA), rifampicin alone, and lactose and maltodextrin carrier particles (bulk and 75-125- microm sieved fractions) were determined by electron microscopy for the projected area diameter (D(p)) and laser diffraction for the volume diameter (D(v)). Surface energies (gamma) of R-PLGA, rifampicin alone, lactose, and maltodextrin were obtained by inverse phase gas chromatography, surface areas (S(a)) by N2 adsorption, and cohesive energy densities by calculation. Particle dispersion was evaluated (Andersen nonviable impactor) for 10% blends of R-PLGA and rifampicin alone with bulk and sieved fractions of the carriers. D(p) for R-PLGA and rifampicin alone was 3.02 and 2.83 microm, respectively. D(v) was 13 +/- 1 and 2 +/- 1 microm for R-PLGA and rifampicin alone, respectively, indicating that R-PLGA was more aggregated. This was evident in gamma of 35 +/- 1 and 19 +/- 6 mJ/m2 for R-PLGA and rifampicin alone. D(p) for lactose and maltodextrin (sieved and bulk) was approximately 40 mm. Bulk maltodextrin (D(v) = 119 +/- 6 microm) was more aggregated than bulk lactose (D(v) = 54 +/- 2 microm). This was a result of the higher S(a) for maltodextrin (0.54 m2/g) than for lactose (0.21 m2/g). The gamma of bulk lactose and maltodextrin was 40 +/- 4 and 60 +/- 6 mJ/m2 and of sieved lactose and maltodextrin was 39 +/- 1 and 50 +/- 1 mJ/m2. Impaction studies yielded higher fine particle fractions of R-PLGA from sieved lactose, 13% +/- 3%, than from sieved maltodextrin, 7% +/- 1%, at 90 L/min. An expression, based on these data, is proposed as a predictor of drug dispersion from carrier particles. Delivery of dry powder formulations can be achieved by characterizing particle surfaces and predicting impact on dispersion.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12916922      PMCID: PMC2751343          DOI: 10.1208/pt030428

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  8 in total

1.  Pharmaceutical dry powder aerosols: correlation of powder properties with dose delivery and implications for pharmacodynamic effect.

Authors:  N M Concessio; M M VanOort; M R Knowles; A J Hickey
Journal:  Pharm Res       Date:  1999-06       Impact factor: 4.200

2.  Latest advances in the development of dry powder inhalers.

Authors: 
Journal:  Pharm Sci Technol Today       Date:  2000-07

3.  Airways delivery of rifampicin microparticles for the treatment of tuberculosis.

Authors:  S Suarez; P O'Hara; M Kazantseva; C E Newcomer; R Hopfer; D N McMurray; A J Hickey
Journal:  J Antimicrob Chemother       Date:  2001-09       Impact factor: 5.790

4.  Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization.

Authors:  P O'Hara; A J Hickey
Journal:  Pharm Res       Date:  2000-08       Impact factor: 4.200

5.  Polymorphism of rifampicin.

Authors:  G Pelizza; M Nebuloni; P Ferrari; G G Gallo
Journal:  Farmaco Sci       Date:  1977-07

6.  The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers--implications for in vitro testing.

Authors:  A R Clark; A M Hollingworth
Journal:  J Aerosol Med       Date:  1993

7.  Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: screening in an infectious disease model.

Authors:  S Suarez; P O'Hara; M Kazantseva; C E Newcomer; R Hopfer; D N McMurray; A J Hickey
Journal:  Pharm Res       Date:  2001-09       Impact factor: 4.200

8.  The use of inverse phase gas chromatography to study the change of surface energy of amorphous lactose as a function of relative humidity and the processes of collapse and crystallisation.

Authors:  H E Newell; G Buckton; D A Butler; F Thielmann; D R Williams
Journal:  Int J Pharm       Date:  2001-04-17       Impact factor: 5.875

  8 in total
  8 in total

Review 1.  Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery.

Authors:  Lauren Willis; Don Hayes; Heidi M Mansour
Journal:  Lung       Date:  2012-01-25       Impact factor: 2.584

2.  Liposomal amikacin dry powder inhaler: effect of fines on in vitro performance.

Authors:  Shrenik P Shah; Ambikanandan Misra
Journal:  AAPS PharmSciTech       Date:  2004-08-09       Impact factor: 3.246

3.  Mouse model for efficacy testing of antituberculosis agents via intrapulmonary delivery.

Authors:  Mercedes Gonzalez-Juarrero; Lisa K Woolhiser; Elizabeth Brooks; Mary Ann DeGroote; Anne J Lenaerts
Journal:  Antimicrob Agents Chemother       Date:  2012-04-30       Impact factor: 5.191

4.  Towards a more desirable dry powder inhaler formulation: large spray-dried mannitol microspheres outperform small microspheres.

Authors:  Waseem Kaialy; Tariq Hussain; Amjad Alhalaweh; Ali Nokhodchi
Journal:  Pharm Res       Date:  2013-08-06       Impact factor: 4.200

5.  Rifampicin-Carbohydrate Spray-Dried Nanocomposite: A Futuristic Multiparticulate Platform For Pulmonary Delivery.

Authors:  Mohammed M Mehanna; Salma M Mohyeldin; Nazik A Elgindy
Journal:  Int J Nanomedicine       Date:  2019-11-22

6.  Rifapentine-proliposomes for inhalation: in vitro and in vivo toxicity.

Authors:  Arpana A Patil-Gadhe; Abhay Y Kyadarkunte; Michael Pereira; Gauri Jejurikar; Milind S Patole; Arun Risbud; Varsha B Pokharkar
Journal:  Toxicol Int       Date:  2014 Sep-Dec

7.  A review of formulations and preclinical studies of inhaled rifampicin for its clinical translation.

Authors:  Prakash Khadka; Jack Dummer; Philip C Hill; Rajesh Katare; Shyamal C Das
Journal:  Drug Deliv Transl Res       Date:  2022-09-21       Impact factor: 5.671

Review 8.  Nanomedicine in pulmonary delivery.

Authors:  Heidi M Mansour; Yun-Seok Rhee; Xiao Wu
Journal:  Int J Nanomedicine       Date:  2009-12-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.